Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
NeuroPace
NPCE
NeuroPace
Rising Regulatory Pressures Will Undermine Neurotech And Spur Cautious Optimism
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
17 Aug 25
Updated
17 Aug 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$13.00
36.5% undervalued
intrinsic discount
17 Aug
US$8.25
Loading
1Y
14.0%
7D
-9.6%
Author's Valuation
US$13.0
36.5% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$13.0
36.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-47m
144m
2019
2021
2023
2025
2027
2028
Revenue US$143.9m
Earnings US$17.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.29%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.06%
Calculation
US$17.87m
Earnings '28
x
41.32x
PE Ratio '28
=
US$738.52m
Market Cap '28
US$738.52m
Market Cap '28
/
45.04m
No. shares '28
=
US$16.40
Share Price '28
US$16.40
Share Price '28
Discounted to 2025 @ 8.05% p.a.
=
US$13.00
Fair Value '25
